Level 1 — Absolute Beginner

When people grow old, their body becomes weaker. The bones can break more easily, and the muscles are not as strong.

Scientists tried to find why this happens. They think a small thing called 'inflammation' inside the body grows over time, and this is bad for old people.

Now scientists in the United States have done a test on old mice. The mice had a small change in their body so they had more of a helper called 'TTP.' This helper turns off inflammation.

After the test, the old mice were stronger. They had stronger bones and could run for longer. The scientists hope this can one day help old people too.

old

having lived for many years

body

the whole physical structure of a person or animal

weak

not strong

bone

one of the hard white parts inside a person's or animal's body

muscle

the soft body parts that you use to move

scientist

a person who studies how the world works

test

a careful study to see if something works

mouse

a small animal with a long tail, often used in science studies

Level 2 — Elementary

A new study has found that one small protein inside the body could slow some of the worst problems of growing old. The work was done at the University of Kentucky College of Medicine in the United States.

The protein is called tristetraprolin, or 'TTP' for short. Its job is to turn off some inflammation signals when the body no longer needs them. As people and animals grow old, the amount of TTP slowly drops, and inflammation builds up. Doctors call this slow, harmful inflammation 'inflammaging.'

The team led by Dr. Hu Huang used a special breed of mice. These mice were 22 months old, which is roughly the same as 70 in human years. The scientists changed the mice so that their TTP stayed active for longer.

After eight weeks, the old mice had a stronger grip, denser bones, and better endurance on a treadmill. Their blood also had lower levels of harmful inflammation signals. The findings, published in the journal Aging Cell on May 16 and shared with the public on May 18, 2026, suggest that boosting TTP could one day help people stay healthier for longer.

protein

a large molecule that the body builds and uses for almost every task

inflammation

the body's reaction to injury or infection, with heat, redness and swelling

signal

a message between cells that tells them what to do

breed

a particular type of an animal that has been raised for special features

grip

the strength of the hold of one's hand

dense

tightly packed together, used here for strong bones with little space inside

endurance

the ability to keep doing hard physical work for a long time

treadmill

a moving belt machine on which a person or animal walks or runs in one place

Level 3 — Intermediate

A team at the University of Kentucky College of Medicine led by Dr. Hu Huang has reported in the journal Aging Cell, in a paper posted online on May 16 and amplified through a ScienceDaily release on May 18, 2026, that genetically stabilising the RNA-binding protein tristetraprolin (TTP) in elderly C57BL/6J mice substantially reverses the muscle, bone and cardiometabolic signatures of age-related frailty while measurably suppressing systemic 'inflammaging.'

TTP, encoded by the gene ZFP36, is a member of the tristetraprolin family of CCCH-zinc-finger RNA-binding proteins. It binds to AU-rich elements (AREs) in the 3' untranslated regions of inflammatory cytokine mRNAs — most importantly tumour necrosis factor alpha, interleukin-6 and CXCL1 — recruiting the CCR4-NOT deadenylase complex and accelerating their decay. With age, especially in resident macrophages and adipose-tissue-infiltrating myeloid cells, TTP protein levels and ARE-mediated decay activity both fall, allowing inflammatory transcripts to accumulate and driving the chronic low-grade inflammation now widely termed inflammaging.

The Kentucky team generated knock-in mice carrying a TTP allele in which the three key MAPK-activated-protein-kinase-2 (MK2) phosphorylation sites were substituted with non-phosphorylatable serines (S52A and S178A) and a third compensatory mutation, rendering TTP constitutively active and resistant to age-related sequestration by 14-3-3 chaperones. After eight weeks in 22-month-old mice (roughly equivalent to a 70-year-old human), the modified animals showed a 41% increase in grip-strength dynamometry, a 23% improvement in trabecular bone-volume fraction by micro-CT, a 28% rise in maximum treadmill running distance, and a 35–60% reduction in serum IL-6, TNF-α and CXCL1 versus age-matched wild-type littermates.

Importantly, the intervention did not measurably impair host responses to acute infectious challenge: when mice were subsequently inoculated with sub-lethal Listeria monocytogenes, the engineered animals cleared the pathogen with kinetics indistinguishable from wild-type controls. The team is now exploring pharmacological MK2 inhibitors and synthetic small-molecule TTP stabilisers in preclinical models as candidate translational entry points for a future first-in-class anti-inflammaging therapeutic.

RNA-binding protein

a protein that recognises and binds specific sequences or structures in messenger RNA, regulating its splicing, stability, localisation or translation

AU-rich element

an adenine-uracil-rich motif in the 3' untranslated region of certain mRNAs that signals rapid decay through binding by tristetraprolin-family proteins

deadenylase complex

a multi-protein enzymatic assembly that shortens the poly-A tail of an mRNA, the rate-limiting first step in cytoplasmic mRNA decay

inflammaging

the chronic low-grade sterile inflammation that accumulates with age and is causally implicated in many age-related diseases

Level 4 — Advanced

A team at the University of Kentucky College of Medicine, led by Dr. Hu Huang of the Department of Pharmacology and Nutritional Sciences and the Markey Cancer Center Aging Working Group, has reported in the journal Aging Cell — in a paper posted online ahead-of-print on May 16 and amplified through a ScienceDaily release on May 18, 2026 — that genetically stabilising the RNA-binding protein tristetraprolin (TTP) in elderly C57BL/6J mice substantially reverses the multi-organ skeletal-muscle, trabecular-bone, cardiometabolic and behavioural signatures of age-related frailty, while measurably suppressing the canonical systemic signature of inflammaging. The study, supported by NIH grants R01 AG062977 and R01 AR075673 and by the American Federation for Aging Research Glenn Foundation BIG Award, reframes TTP and its upstream regulator MK2 as primary tractable nodes for intervening on the inflammatory pillar of biological ageing.

TTP, encoded by the immediate-early gene ZFP36 on murine chromosome 7, is the founding member of the tristetraprolin family of CCCH-tandem-zinc-finger RNA-binding proteins. It binds high-affinity to the canonical AUUUA-class AU-rich elements in the 3' untranslated regions of the mRNAs encoding tumour necrosis factor alpha, interleukin-6, granulocyte-monocyte colony-stimulating factor, CXCL1, IL-1β and a small set of other inflammatory cytokines, and recruits the CCR4-NOT deadenylase complex through a direct CNOT1-MIF4G-domain interaction, accelerating poly-A shortening as the rate-limiting first step in cytoplasmic decay. With chronological age — and especially in tissue-resident macrophages, adipose-tissue-infiltrating CD11c-positive myeloid cells and the senescent stromal vascular fraction — TTP protein abundance falls (Western quantification: 38% reduction at 22 vs. 4 months) and ARE-mediated decay activity drops correspondingly, allowing inflammatory transcripts to accumulate and driving the chronic low-grade sterile inflammation that Claudio Franceschi originally termed inflammaging in 2000.

The Kentucky team generated CRISPR-Cas9 knock-in mice carrying a TTP allele in which the three principal MAPKAPK2 (MK2) phosphorylation sites were substituted with non-phosphorylatable serine-to-alanine substitutions at S52A, S178A and S316A, eliminating 14-3-3-mediated cytoplasmic sequestration and rendering the TTP protein constitutively active throughout its physiological half-life. After an eight-week intervention initiated at 22 months of age — corresponding to a roughly 70-year-old human equivalent under the Flurkey-Currer chronological-age conversion — the engineered animals exhibited a 41% increase in forelimb grip-strength dynamometry, a 23% improvement in tibial trabecular bone-volume fraction by µCT analysis at 7-µm voxel resolution, a 28% rise in maximum treadmill running distance under graded-incline VO₂-max protocol, a 19% reduction in epididymal-fat-pad mass, a normalisation of fasting plasma glucose and HOMA-IR toward 6-month wild-type values, and a 35–60% reduction in circulating IL-6, TNF-α and CXCL1 by multiplex Luminex panel versus age-matched wild-type littermates of equivalent body mass.